La Jolla Pharmaceutical Company (LJPC) was Initiated by Lake Street to “Buy” and the brokerage firm has set the Price Target at $25. Lake Street advised their investors in a research report released on May 24, 2016.
La Jolla Pharmaceutical Company opened for trading at $14.95 and hit $15.6 on the upside on Friday, eventually ending the session at $15.5, with a gain of 4.24% or 0.63 points. The heightened volatility saw the trading volume jump to 88,086 shares. Company has a market cap of $282,937 M.
In a different news, on Sep 30, 2015, Lakhmir S Chawla (Chief Medical Officer) purchased 485 shares at $27.75 per share price. According to the SEC, on May 15, 2015, Saiid Zarrabian (director) purchased 307 shares at $19.50 per share price. On May 13, 2015, George F Tidmarsh (CEO) purchased 4,000 shares at $18.37 per share price, according to the Form-4 filing with the securities and exchange commission.
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. Its four product candidates in development include LJPC-501 GCS-100 LJPC-1010 and LJPC-401. LJPC-501 is its formulation of angiotensin for the treatment of catecholamine-resistant hypotension (CRH). GCS-100 is its galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010 is its galectin-3 inhibitor. LJPC-401 is its formulation of hepcidin for the potential treatment of conditions characterized by iron overload such as hemochromatosis and beta thalassemia.